CV

Prof. Maggie Christine Walter, MD, MA

Personal data

Name:	Maggie Christine WALTER
Date of birth:	19. 12. 1964
Place of birth:	Baden-Baden, Germany
Nationality:	German
Family status:	In permanent partnership, 2 daughters, 18 & 26 y.
Home address:	Kaiserstr. 17, 80801 Munich, Germany
Private phone:	+49-174-3053535

Work address

Friedrich-Baur-Institute
Dept. of Neurology
Ludwig-Maximilians-University
Ziemssenstr. 1a
80336 Munich, Germany
Phone: +49-89-4400-57400
Fax: +49-89-4400-57402
Email: maggie.walter@lrz.uni-muenchen.de

Education and Training

1985 - 1994	Medical school, LMU Munich, Germany
07/1998	Dissertation LMU Munich "Sleep endocrinologic effects of steroid receptor agonists and antagonists in healthy volunteers ("magna cum laude")
1995-2005	Resident/Consultant, Dept. of Neurology and Friedrich-Baur-Institute, LMU Munich, Germany
01/2005	Postdoctoral lecture qualification / State doctorat ("Privatdozent")
01/2006	Approval as a medical specialist for Neurology
2007 – 2010	Extra-occupational studies - Master „Health Care Management", TU Kaiserslautern, Kaiserslautern, Germany Health Care Management", TU Kaiserslautern, „Master of Arts"
02/2012	Qualification in "neurology-specific genetic counseling", Bavarian Medical Association
06/2013	Qualification in „Nutritional Medicine DAEM/DGEM", German academy and German society for Nutritional Medicine

Positions and Employment

1995-2005	Resident/Consultant, Dept. of Neurology and Friedrich-Baur-Institute, LMU Munich, Germany
2005 - 2010	Assistant Professor for Neurology, Friedrich-Baur-Institute, Munich, Germany
2011 – cont.	Associate Professor for Neurology, Friedrich-Baur-Institute, Munich, Germany
08/2008 - 03/2012	Leader Workpackage A04: „Biobanking and patient registries" 6th EU FP NoE TREAT-NMD (www.treat-nmd.eu)
04/2008 – cont.	Network Coordinator, Network for Rare Diseases, German Muscular Dystrophy Network MD-NET (www.md-net.org), funded by the German Ministry for Education and Research (BMBF)
01/2016 – cont.	Network Co-Coordinator, Network for Rare Diseases, German Charcot-Marie-Tooth Neuropathy Network (CMT-NET, www.cmt-net.org)

Awards

2000	Sanofi Award for Research in Neuromuscular Diseases by the "Deutsche Gesellschaft für Muskelkranke" (DGM), Freiburg, Germany
2007	Poster award DGKN, "Identification of a desmin gene mutation in scapuloperoneal syndrome type Kaeser", 51th Annual Meeting of the "German Society for Clinical Neurophysiology and Functional Imaging", Munich, 21st – 25th March, 2007.
2014	Felix-Jerusalem Award by the „Deutsche Gesellschaft für Muskelkranke e.V. (DGM e.V.), Freiburg, Germany. "Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle".

Ad hoc Reviewer

2001 – cont.	American Journal of Human Genetics, American Journal of Medical Genetics, Journal of Neurology, Journal of Neurology, Neurosurgery and Psychiatry, Neurology, Neuromuscular disorders, Nervenarzt, Muscle&Nerve, Science Translational Medicine, PloS ONE Grant reviews: German Federal Ministry for Education and Research (BMBF), aktion benni & co, Germany, Telethon, Italy, Association Française contre les Myopathies (AFM), France

Experience with clinical trials

1997 – 2000	High-dose immunoglobulin therapy (IVIG) in inclusion body myositis (IBM): A double-blind, placebo-controlled study (PI)
1998 – 2000	Creatine Monohydrate in Muscular Dystrophies: A Double-Blind, Placebo-

	Controlled Clinical Study (PI)
1998 – 2000	Creatine monohydrate in mitochondrial diseases. A double-blind, placebo-controlled, cross-over study in 16 patients with chronic progressive external ophtalmoplegia or mitochondrial myopathy (CI)
2001	Participation in the 94th ENMC workshop on Basic methodologies for clinical trials in neuromuscular disorders. Naarden, The Netherlands, 11-13th of May, 2001
2000 – 2002	Creatine Monohydrate in Myotonic Dystrophy - a Double-Blind, Placebo-Controlled Clinical Study (PI)
2004	Participation in the 124th ENMC International Workshop on Treatment of Duchenne muscular dystrophy-defining the gold standards of management. Naarden, the Netherlands, April 2-4th 2004
2002 – 2009	Deflazacort in Dysferlinopathies - a Double-Blind, Placebo-Controlled Clinical Study (PI), funded by the German Federal Ministry for Education and Research (BMBF) within the MD-NET
2011 – 2013	Phase II, multicenter, randomized, adaptive, double-blind, placebo controlled study to assess safety and efficacy of olesoxime (TRO19622) in 3-25 year old Spinal Muscular Atrophy (SMA) patients. *EudraCT Number: 2008-007320-25.*
2012 – 2017	International clinical outcome study for dysferlinopathy – Jain Foundation
2013 – 2014	Retrospective cohort study in Congenital Cataract Facial Dysmorphism Neuropathy Syndrome (CCFDN), sporadic inclusion myositis (sIBM) and hereditary inclusion body myopathy (hIBM)
2016 - ongoing	International, multi-center, randomized, double-blind, placebo-controlled phase III study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A treated 15 months. *EudraCT Number: 2015-002378-19.*
2016 - ongoing	CMT-NET Clinical Trial C1 - Natural history and risk factors in CMT during development

Most important articles

Schreiber-Katz O, Klug C, Thiele S, Schorling E, Zowe J, Reilich P, Nagels K*, **Walter MC***. Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies. OJRD 2014;9:210. *= equal contribution.

Walter MC, Bernert G, Zimmermann U, Müllner-Eidenböck A, Moser E, Kalaydjieva L, Lochmüller H, Müller-Felber W. Long-term follow-up in patients with Congenital Cataract Facial Dysmorphism Neuropathy (CCFDN) Syndrome. Neurology 2014;83:1337-1344.

Klymiuk N, Blutke A, Graf A, Krause S, Burkhardt K, Wuensch A, Krebs S, Kessler B, Zakhartchenko V, Kurome M, Kemter E, Nagashima H, Schoser B, Herbach N, Blum H, Wanke R, Aartsma-Rus A, Thirion C, Lochmüller H*, **Walter MC*** Wolf E*. Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle. Hum Mol Genet 2013;22:4368-4382. *= equal contribution.

Walter MC, Reilich P, Huebner A, Fischer D, Schröder R, Vorgerd M, Kress W, Born C, Schoser BG, Krause KH, Klutzny U, Bulst S, Frey JR, Lochmüller H. Scapuloperoneal syndrome type Kaeser and a wide phenotypic spectrum of adult-onset, dominant myopathies are associated with the desmin mutation R350P. Brain 2007;130:1485-1496.

Varon R, Gooding R, Steglich C, Marns L, Tang H, Angelicheva D, Yong KK, Ambrugger P, Reinhold A, Morar B, Baas F, Kwa M, Tournev I, Guerguelcheva V, Kremensky I, Lochmüller H, Müllner-Eidenböck A, Merlini L, Neumann L, Bürger J, **Walter M**, Swoboda K, Thomas PK, von Moers A, Risch N, Kalaydjieva L. Partial deficiency of the C-terminal-domain phosphatase of RNA polymerase II is associated with congenital cataracts facial dysmorphism neuropathy syndrome. Nat Genet 2003, 35:185-189.



24.04.2018

Prof. Maggie C. Walter, MD, MA